Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Launches Third Celgene Cancer Drug in China

publication date: Feb 6, 2018

Beijing's BeiGene has launched Vidaza® in China. Vidaza is a nucleoside metabolic inhibitor that is approved in China for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocyte leukemia (CMML). BeiGene acquired rights to Vidaza when it took over Celgene's China sales organization as part of the blockbuster $1.4 billion deal that gave Celgene global rights (ex-China) to BeiGene's PD-1 immunotherapy in 2017. More details....

Stock Symbols: (NSDQ: BGNE) (NSDQ: CELG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.